Header Logo

Connection

PAVAN REDDY to Hematopoietic Stem Cell Transplantation

Back to Details
This is a "connection" page, showing publications PAVAN REDDY has written about Hematopoietic Stem Cell Transplantation.
PAVAN REDDY
Connection Strength
7.161
Hematopoietic Stem Cell Transplantation
  1. Autophagy differentially regulates tissue tolerance of distinct target organs in graft-versus-host disease models. J Clin Invest. 2024 Mar 01; 134(5).
    View in: PubMed
    Score: 0.453
  2. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood. 2024 01 04; 143(1):21-31.
    View in: PubMed
    Score: 0.448
  3. Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation. Nat Med. 2023 11; 29(11):2805-2813.
    View in: PubMed
    Score: 0.441
  4. Ambient oxygen levels regulate intestinal dysbiosis and GVHD severity after allogeneic stem cell transplantation. Immunity. 2023 02 14; 56(2):353-368.e6.
    View in: PubMed
    Score: 0.420
  5. RNA-seq of human T cells after hematopoietic stem cell transplantation identifies Linc00402 as a regulator of T cell alloimmunity. Sci Transl Med. 2021 03 17; 13(585).
    View in: PubMed
    Score: 0.369
  6. Targeting Signal 3 Extracellularly and Intracellularly in Graft-Versus-Host Disease. Front Immunol. 2020; 11:722.
    View in: PubMed
    Score: 0.347
  7. Microbes and Their Metabolites Correlate with Hematopoietic Stem Cell Transplantation Outcomes? Biol Blood Marrow Transplant. 2018 12; 24(12):e7-e8.
    View in: PubMed
    Score: 0.314
  8. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation. J Immunol. 2018 12 01; 201(11):3443-3455.
    View in: PubMed
    Score: 0.313
  9. Non-Coding RNA Mediated Regulation of Allogeneic T Cell Responses After Hematopoietic Transplantation. Front Immunol. 2018; 9:1110.
    View in: PubMed
    Score: 0.305
  10. Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT. Blood. 2017 10 12; 130(15):1760-1767.
    View in: PubMed
    Score: 0.287
  11. Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans. Blood. 2015 Jan 29; 125(5):815-9.
    View in: PubMed
    Score: 0.238
  12. Current and emerging strategies for the prevention of graft-versus-host disease. Nat Rev Clin Oncol. 2014 Sep; 11(9):536-47.
    View in: PubMed
    Score: 0.231
  13. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014 Jan; 15(1):87-95.
    View in: PubMed
    Score: 0.222
  14. GVHD pathophysiology: is acute different from chronic? Best Pract Res Clin Haematol. 2008 Jun; 21(2):101-17.
    View in: PubMed
    Score: 0.152
  15. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Transplantation. 2008 Feb 15; 85(3):303-8.
    View in: PubMed
    Score: 0.149
  16. Cognitive Functioning in Vorinostat-Treated Pediatric and Young Adult Patients Over the First 180 Days After Hematopoietic Stem Cell Transplant. Pediatr Blood Cancer. 2026 Jun; 73(6):e70259.
    View in: PubMed
    Score: 0.131
  17. Novel regulators of GVHD revealed through microbiome and metabolome patterns across distinct intestinal regions. Blood. 2025 Jun 05; 145(23):2774-2787.
    View in: PubMed
    Score: 0.124
  18. Oral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host disease. Blood. 2025 Feb 20; 145(8):881-896.
    View in: PubMed
    Score: 0.121
  19. Recruitment and Retention of Hematopoietic Cell Transplantation and Cellular Therapy Physicians: A Report from the ASTCT Talent Acquisition Task Force. Transplant Cell Ther. 2024 06; 30(6):559-564.
    View in: PubMed
    Score: 0.114
  20. Allogeneic T cells cause acute renal injury after hematopoietic cell transplantation. Blood Adv. 2023 11 28; 7(22):6936-6948.
    View in: PubMed
    Score: 0.111
  21. Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment. Sci Transl Med. 2022 11 16; 14(671):eabo3445.
    View in: PubMed
    Score: 0.104
  22. Prevention and Treatment of Acute Graft-versus-Host Disease in Children, Adolescents, and Young Adults. Biol Blood Marrow Transplant. 2020 05; 26(5):e101-e112.
    View in: PubMed
    Score: 0.085
  23. Computational analysis of continuous body temperature provides early discrimination of graft-versus-host disease in mice. Blood Adv. 2019 12 10; 3(23):3977-3981.
    View in: PubMed
    Score: 0.084
  24. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2019 08; 25(8):1492-1497.
    View in: PubMed
    Score: 0.081
  25. Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 08; 25(8):1682-1688.
    View in: PubMed
    Score: 0.080
  26. Cognitive Function and Quality of Life in Vorinostat-Treated Patients after Matched Unrelated Donor Myeloablative Conditioning Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):343-353.
    View in: PubMed
    Score: 0.078
  27. The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biol Blood Marrow Transplant. 2018 07; 24(7):1322-1340.
    View in: PubMed
    Score: 0.075
  28. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival. JCI Insight. 2017 02 09; 2(3):e89798.
    View in: PubMed
    Score: 0.069
  29. Tissue tolerance: a distinct concept to control acute GVHD severity. Blood. 2017 03 30; 129(13):1747-1752.
    View in: PubMed
    Score: 0.069
  30. Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Mar; 23(3):522-528.
    View in: PubMed
    Score: 0.069
  31. Advances in understanding the pathogenesis of graft-versus-host disease. Br J Haematol. 2016 Apr; 173(2):190-205.
    View in: PubMed
    Score: 0.065
  32. Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. Biol Blood Marrow Transplant. 2016 May; 22(5):862-8.
    View in: PubMed
    Score: 0.064
  33. Acute Graft-versus-Host Disease: Novel Biological Insights. Biol Blood Marrow Transplant. 2016 Jan; 22(1):11-6.
    View in: PubMed
    Score: 0.063
  34. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series. Biol Blood Marrow Transplant. 2016 Jan; 22(1):54-60.
    View in: PubMed
    Score: 0.062
  35. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant. 2016 Apr; 51(4):511-520.
    View in: PubMed
    Score: 0.062
  36. Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol. 2015 Jun; 94(6):1033-41.
    View in: PubMed
    Score: 0.061
  37. Participation in clinical research: perspectives of adult patients and parents of pediatric patients undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1604-11.
    View in: PubMed
    Score: 0.058
  38. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1407-17.
    View in: PubMed
    Score: 0.058
  39. Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1426-34.
    View in: PubMed
    Score: 0.058
  40. ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013 Aug 08; 369(6):529-39.
    View in: PubMed
    Score: 0.054
  41. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)? Curr Stem Cell Res Ther. 2012 May; 7(3):229-39.
    View in: PubMed
    Score: 0.050
  42. TNF-inhibition with etanercept for graft-versus-host disease prevention in high-risk HCT: lower TNFR1 levels correlate with better outcomes. Biol Blood Marrow Transplant. 2012 Oct; 18(10):1525-32.
    View in: PubMed
    Score: 0.050
  43. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood. 2012 Mar 22; 119(12):2960-3.
    View in: PubMed
    Score: 0.049
  44. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. 2011 Oct 13; 118(15):4258-64.
    View in: PubMed
    Score: 0.047
  45. Emerging drugs for acute graft-versus-host disease. Expert Opin Emerg Drugs. 2009 Jun; 14(2):219-32.
    View in: PubMed
    Score: 0.041
  46. Graft-versus-host disease. Lancet. 2009 May 02; 373(9674):1550-61.
    View in: PubMed
    Score: 0.040
  47. A biomarker panel for acute graft-versus-host disease. Blood. 2009 Jan 08; 113(2):273-8.
    View in: PubMed
    Score: 0.039
  48. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008 Feb 15; 111(4):2470-5.
    View in: PubMed
    Score: 0.037
  49. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res. 2007 Oct; 150(4):197-214.
    View in: PubMed
    Score: 0.036
  50. Bacteroides ovatus alleviates dysbiotic microbiota-induced graft-versus-host disease. Cell Host Microbe. 2024 Sep 11; 32(9):1621-1636.e6.
    View in: PubMed
    Score: 0.029
  51. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. Blood. 2018 06 21; 131(25):2846-2855.
    View in: PubMed
    Score: 0.019
  52. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 03; 24(3):282-291.
    View in: PubMed
    Score: 0.019
  53. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011 Dec 15; 118(25):6702-8.
    View in: PubMed
    Score: 0.012
  54. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003 Aug; 9(8):505-11.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.